Transforming global health with next generation, precision vaccines
Who We Are
Virometix AG is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases. Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a proprietary modular and fully synthetic nanoparticle technology platform, our vaccines are purposefully designed, safe, cost effective and scalable. Our lead indication for Streptococcus pneumoniae infections targets a high unmet need.
Purposely Engineered Immune Protection
Our flexible, modular synthetic technology platform offers competitive vaccine advantages including enhanced efficacy through broad coverage. We use structural insights and algorithms to design immunogens that imitate key protective targets on infectious microbes and display them in multiple copies on special particles that naturally boost the immune response without needing extra adjuvants. In preclinical studies, our synthetic nanoparticle delivery platform has been shown to be safe, immunogenic and protective against target pathogens.
Pipeline
Our technology platform lends itself to a wide range of applications. We are developing a portfolio of products highlighted by a first-in-class serotype-independent vaccine candidate against Streptococcus pneumoniae, and a reverse engineered, epitope-specific vaccine candidates for Respiratory Syncytial Virus.
Grants & Awards
Our awards include the following
